

RESEARCH AND CLINICAL APPLICATION OF THE MENOPAUSE-SPECIFIC QUALITY OF LIFE (MENQOL) QUESTIONNAIRE: A COMPREHENSIVE SYSTEMATIC REVIEW

Beate C Sydora, PhD; Hilary Fast, MA; Sandy Campbell, MLS; Nese Yuksel, PharmD; Kathleen Hegadoren, PhD; Tami Shandro, MD; Nan Schuurmans, MD; Jacqueline Lewis, MD; Sue J Ross, PhD. Mature Women's Health Clinic, Royal Alexandra Hospital, and Department of Obstetrics and Gynecology, University of Alberta, Edmonton

Background

 \succ The menopause-specific quality of life (MENQOL) questionnaire was developed as a validated research tool to measure condition-specific quality of life in early postmenopausal women.

 \succ Since its introduction in 1996, it has been increasingly used in women's health clinical trials and menopause research worldwide.

The exact extent and relevance of MENQOL usage in medical research is not known.

Objectives

To examine the use of MENQOL in research and clinical settings over the past 16 years in order to assess its value in providing patient assessment information to clinicians, patients, and healthcare workers.

Study Methods

We conducted a systematic review of articles published between 1996 and 2012 using 'mengol' as the search word to screen 13 biomedical and clinical data bases.

Additional articles were collected from references within key articles.

Duplicates were removed in RefWorks reference manager.

Included were all studies using MENQOL or its further development MENQOL-Intervention as a tool. Excluded were review articles, dissertations, meeting abstracts and proceedings, incomplete clinical trials, articles that only cite MENQOL, and foreign language duplicates.

Data were extracted and charted according to:

- Author, year of publication, country and language
- Study design and intervention,
- Participant number, age, menopausal stage,
- MENQOL version(original, Intervention, adaptation)



were represented in the 166 articles.

Results and Data Analysis

Additional records identified through citations in selected articles, including reviews and dissertations (n = 307)

> Duplicate records excluded (n = 543)

Records excluded, according to exclusion criteria (n = 468)

Full-text articles excluded, according to lack of inclusion criteria (n = 87)

er (%)	of articles,
5	
(39.16)	
(3.61)	
(39.16)	
(16.27)	
(3.61)	
(1.81)	
(18.07)	
(7.83)	
(12.04)	
(6.02)	
(6.02)	
(9.64)	
(43.37)	

Table 2: Participants' age and menopausal stage

Age ^a

Target range

Target range &

Target range

Target range & older& Not s

Menopausal stage ^a

Post-menopau

Peri-menopau

Pre-menopau

Post-& peri-men

Post- & pre-men Post, peri-, & pre-men

Not s

^a: MENQOL target population: postmenopausal women age 40 to 65.

More than half of the 166 articles confined their study to women with the age and menopause stage for which MENQOL was validated (in bold).

Table 3: Analytical Methodology

Version used ^a	Total (% of	Item number ^b	Report on past ^b	Scoring ^b
	N=166)	29+1/32+1	1week/1month	1 to 8
MENQOL	115 (69.28)	97/115	44/115	35/115
MENQOL-Intervention	12 (7.23)	11/12	3/12	3/12
Modified version	12 (7.23)		4/12	5/12
Not specified	27 (16.27)		3/27	

^a: Original MENQOL :29 items plus one QOL question, report on past one month, scoring 1 to 8 MENQOL-Intervention :32 items plus one QOL question, report on past one week, scoring 1 to 8. ^b: Numbers indicate use of correct questionnaire item number, reporting period, and scoring.

Only 18 articles reported on the proper usage of all 3 analytical properties.



Our data indicate that the MENQOL questionnaire has found extensive use over the past 16 years in research and clinical studies of various designs. However, few articles appear to use the validated analytical methodology. Used in the appropriate and validated form, MENQOL emerges as a valuable tool for the assessment of menopausal women.

Acknowledgements:





Number (%) of articles, N=	=166
93 (56.02)	
9 (5.42)	
19 (11.45)	
10 (6.02)	
35 (21.08)	
85 (51.20)	
8 (4.81)	
2 (1.20)	
33 (19.88)	
2 (1.20)	
25 (15.06)	
11 (6.63)	
	93 (56.02) 9 (5.42) 19 (11.45) 10 (6.02) 35 (21.08) 85 (51.20) 8 (4.81) 2 (1.20) 33 (19.88) 2 (1.20) 25 (15.06)

Conclusions



